...
search icon
itos-img

Iteos Therapeutics Inc, Common Stock

ITOS

NMQ

$5.65

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$210.45M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
191.47K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.43
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.8 L
$18.75 H
$5.65

About Iteos Therapeutics Inc, Common Stock

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameITOSSectorS&P500
1-Week Return4.82%1.18%5.38%
1-Month Return-19.97%-6.29%-4.05%
3-Month Return-27.56%-3.24%-8.24%
6-Month Return-43.22%-11.06%-7.91%
1-Year Return-54.07%-2.94%3.04%
3-Year Return-83.37%-2.23%21.3%
5-Year Return-70.34%45.61%93.75%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-344.77M267.63M12.60M35.00M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.62,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true},{"date":"2024-12-31","value":10.15,"profit":true}]
Cost of Revenue535.00K615.00K813.00K898.00K-[{"date":"2020-12-31","value":59.58,"profit":true},{"date":"2021-12-31","value":68.49,"profit":true},{"date":"2022-12-31","value":90.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(535.00K)344.16M266.82M11.70M35.00M[{"date":"2020-12-31","value":-0.16,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":77.53,"profit":true},{"date":"2023-12-31","value":3.4,"profit":true},{"date":"2024-12-31","value":10.17,"profit":true}]
Gross Margin-99.82%99.70%92.87%100.00%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":99.82,"profit":true},{"date":"2022-12-31","value":99.7,"profit":true},{"date":"2023-12-31","value":92.87,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses39.31M89.69M138.04M163.70M194.53M[{"date":"2020-12-31","value":20.21,"profit":true},{"date":"2021-12-31","value":46.11,"profit":true},{"date":"2022-12-31","value":70.96,"profit":true},{"date":"2023-12-31","value":84.15,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(45.24M)244.90M126.32M(151.10M)(159.53M)[{"date":"2020-12-31","value":-18.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":51.58,"profit":true},{"date":"2023-12-31","value":-61.7,"profit":false},{"date":"2024-12-31","value":-65.14,"profit":false}]
Total Non-Operating Income/Expense-11.64M33.77M72.97M70.06M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":15.95,"profit":true},{"date":"2022-12-31","value":46.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":96.01,"profit":true}]
Pre-Tax Income(38.09M)256.46M148.74M(109.03M)(120.34M)[{"date":"2020-12-31","value":-14.85,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.99,"profit":true},{"date":"2023-12-31","value":-42.51,"profit":false},{"date":"2024-12-31","value":-46.92,"profit":false}]
Income Taxes(57.00K)41.94M52.08M3.61M14.07M[{"date":"2020-12-31","value":-0.11,"profit":false},{"date":"2021-12-31","value":80.53,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.93,"profit":true},{"date":"2024-12-31","value":27.02,"profit":true}]
Income After Taxes-214.52M96.65M(112.64M)(134.41M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false},{"date":"2024-12-31","value":-62.66,"profit":false}]
Income From Continuous Operations(38.03M)214.52M96.65M(61.64M)(134.41M)[{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-28.73,"profit":false},{"date":"2024-12-31","value":-62.66,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(38.03M)214.52M96.65M(112.64M)(134.41M)[{"date":"2020-12-31","value":-17.73,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.05,"profit":true},{"date":"2023-12-31","value":-52.51,"profit":false},{"date":"2024-12-31","value":-62.66,"profit":false}]
EPS (Diluted)(30.82)5.612.56(3.15)(3.33)[{"date":"2020-12-31","value":-549.29,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":45.63,"profit":true},{"date":"2023-12-31","value":-56.15,"profit":false},{"date":"2024-12-31","value":-59.39,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ITOS
Cash Ratio 12.26
Current Ratio 12.62

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ITOS
ROA (LTM) -14.47%
ROE (LTM) -23.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ITOS
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ITOS
Trailing PE NM
Forward PE 12.56
P/S (TTM) 6.17
P/B 0.37
Price/FCF 40
EV/R 1.26
EV/Ebitda 0.50

FAQs

What is Iteos Therapeutics Inc share price today?

Iteos Therapeutics Inc (ITOS) share price today is $5.65

Can Indians buy Iteos Therapeutics Inc shares?

Yes, Indians can buy shares of Iteos Therapeutics Inc (ITOS) on Vested. To buy Iteos Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ITOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Iteos Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Iteos Therapeutics Inc (ITOS) via the Vested app. You can start investing in Iteos Therapeutics Inc (ITOS) with a minimum investment of $1.

How to invest in Iteos Therapeutics Inc shares from India?

You can invest in shares of Iteos Therapeutics Inc (ITOS) via Vested in three simple steps:

  • Click on Sign Up or Invest in ITOS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Iteos Therapeutics Inc shares
What is Iteos Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Iteos Therapeutics Inc (ITOS) is $18.75. The 52-week low price of Iteos Therapeutics Inc (ITOS) is $4.8.

What is Iteos Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Iteos Therapeutics Inc (ITOS) is 0.37

What is the Market Cap of Iteos Therapeutics Inc?

The market capitalization of Iteos Therapeutics Inc (ITOS) is $210.45M

What is Iteos Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Iteos Therapeutics Inc is ITOS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top